知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.012 seconds)

    Heterocyclic compounds
    1.
    发明申请
    Heterocyclic compounds 审中-公开
    杂环化合物

    公开(公告)号：US20120041195A1

    公开(公告)日：2012-02-16

    申请号：US13201165

    申请日：2010-02-09

    Applicant: Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David Middlemiss

    Inventor： Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David Middlemiss

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted triazolopyridine compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder. In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

    Abstract translation: 本发明涉及某些新化合物，其制备方法和用于治疗或改善激酶介导的病症的方法。 更具体地，本发明涉及可用作选择性激酶抑制剂的取代的三唑并吡啶化合物，用于制备这些化合物的方法和用于治疗或改善激酶介导的病症的方法。 特别地，所述方法涉及治疗或改善包括心血管疾病，糖尿病，糖尿病相关疾病，炎性疾病，免疫学疾病，癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病的激酶介导的疾病，以及 类似。

    SUBSTITUTED QUINAZOLINE COMPOUNDS
    2.
    发明申请
    SUBSTITUTED QUINAZOLINE COMPOUNDS 失效
    取代的喹啉腈化合物

    公开(公告)号：US20120004210A1

    公开(公告)日：2012-01-05

    申请号：US13142333

    申请日：2009-12-18

    Applicant: Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David Middlemiss

    Inventor： Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David Middlemiss

    IPC: A61K31/517 ,  C07D403/14 ,  C07D401/14 ,  A61K31/55 ,  A61P27/02 ,  A61P3/10 ,  A61P29/00 ,  A61P37/00 ,  A61P35/00 ,  C07D403/12 ,  A61P9/00

    CPC classification number: C07D401/14 ,  C07D403/04

    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

    Abstract translation: 本发明涉及某些新化合物，其制备方法和用于治疗或改善激酶介导的病症的方法。 更具体地，本发明涉及可用作选择性激酶抑制剂的取代喹唑啉化合物，用于制备这些化合物的方法和用于治疗或改善激酶介导的病症的方法。特别地，所述方法涉及治疗或改善激酶介导的病症，包括 心血管疾病，糖尿病，糖尿病相关疾病，炎性疾病，免疫学障碍，癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病等。

    STABLE PROBIOTIC GRANULATE, AND METHOD FOR PREPARING SAME
    3.
    发明申请
    STABLE PROBIOTIC GRANULATE, AND METHOD FOR PREPARING SAME 审中-公开
    稳定的生物颗粒及其制备方法

    公开(公告)号：US20120003317A1

    公开(公告)日：2012-01-05

    申请号：US13255110

    申请日：2010-03-09

    Applicant: Amelie Hiolle ,  Cecile Sampsonis ,  Eric Auclair ,  Christian Lenoir

    Inventor： Amelie Hiolle ,  Cecile Sampsonis ,  Eric Auclair ,  Christian Lenoir

    IPC: A61K9/14 ,  A61P1/00 ,  A61K35/66

    CPC classification number: A23K10/18 ,  A23K40/10 ,  A23L33/14 ,  A23P10/25 ,  A23V2002/00 ,  A23V2200/3204 ,  A23V2200/254

    Abstract: The invention pertains to the field of probiotic compositions useful for human and/or animal food and health. The invention particularly relates to compositions containing stable probiotic microorganisms during the production of tablets or granules for final use. The works of the applicant of the present invention show that the mortality of probiotic microorganisms during granulation is closely linked with granulation operating conditions and with the characteristics of the selected microorganisms. Said works have led to the establishment of a mathematical expression for defining both the characteristics of the yeast as well as the parameters of the method so that the microorganism losses after granulation are lower than 1 log CFU/g of granulated food.

    Abstract translation: 本发明涉及可用于人和/或动物食物和健康的益生菌组合物领域。 本发明特别涉及在生产用于最终用途的片剂或颗粒期间含有稳定的益生菌微生物的组合物。 本发明申请人的作品表明，造粒期间益生菌微生物的死亡率与造粒操作条件和所选微生物的特性密切相关。 所述作品已经导致建立了用于定义酵母的特征以及该方法的参数的数学表达式，使得造粒后的微生物损失低于1log CFU / g的粒状食物。

    Substituted quinazoline compounds
    4.
    发明授权
    Substituted quinazoline compounds 失效
    取代喹唑啉化合物

    公开(公告)号：US08389530B2

    公开(公告)日：2013-03-05

    申请号：US13142333

    申请日：2009-12-18

    Applicant: Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David N. Middlemiss

    Inventor： Caroline Leriche ,  Eric Auclair ,  Jacques Le Roux ,  David N. Middlemiss

    IPC: A01N43/54 ,  A61K31/517 ,  C07D401/00

    CPC classification number: C07D401/14 ,  C07D403/04

    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

    Abstract translation: 本发明涉及某些新化合物，其制备方法和用于治疗或改善激酶介导的病症的方法。 更具体地，本发明涉及可用作选择性激酶抑制剂的取代喹唑啉化合物，用于制备这些化合物的方法和用于治疗或改善激酶介导的病症的方法。特别地，所述方法涉及治疗或改善激酶介导的病症，包括 心血管疾病，糖尿病，糖尿病相关疾病，炎性疾病，免疫学障碍，癌症和眼睛疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病等。

Patent Agency Ranking